A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta

This is a long-term safety registry tracking children and adults with high-risk neuroblastoma — a type of cancer that usually starts in the adrenal glands — who are being treated with a drug called dinutuximab beta. The registry collects data for up to 10 years to monitor safety and outcomes. **You may be eligible if:** - You (or your child) has been diagnosed with high-risk neuroblastoma - You are starting treatment with dinutuximab beta through commercial supply or via an approved clinical trial - You (or your child's guardian) are willing to be followed for up to 10 years **You may NOT be eligible if:** - The dinutuximab beta is being used in a clinical trial where the drug is supplied outside of its approved marketing authorization Talk to your doctor to see if this trial is right for you.